title: Hepatitis C Virus: Current and Evolving Treatments for Genotypes 2 and 3.
abstract: Hepatitis C virus (HCV) genotypes 2 and 3 have previously been classified as easy-to-treat genotypes, because sustained virologic responses (SVRs) up to 80% have been achieved with 24-week peginterferon and ribavirin. More detailed studies have shown differences between HCV genotypes 2 and 3, indicating that genotype 3 has become the most difficult-to-treat genotype. With new drugs, new challenges are emerging regarding relapse rates, the role of ribavirin, and optimal duration of therapy. Sofosbuvir remains the backbone of genotype 3 therapy, whereas this drug is not an option in patients with creatinine clearance lower than 30 mL/min.
authors.affiliation: Unit for the Clinical Management of Digestive Diseases & CIBERehd, Virgen Macarena - Virgen del Rocio University Hospitals, Avenida Manuel Siurot, s/n, Sevilla 41017, Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: Ampuero
authors.affiliation: Unit for the Clinical Management of Digestive Diseases & CIBERehd, Virgen Macarena - Virgen del Rocio University Hospitals, Avenida Manuel Siurot, s/n, Sevilla 41017, Spain. Electronic address: mromerogomez@us.es.
authors.forename: Manuel
authors.initials: M
authors.lastname: Romero-Gómez
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents
keywords: Direct-acting antiviral; Genotype 2; Genotype 3; Hepatitis C; Sustained virologic response